Overview

CLN-0046: Treatment of AMD Subjects With OTX-TKI

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

To evaluate the safety, tolerability and efficacy of OTX-TKI for intravitreal use, in subjects who have neovascular age-related macular degeneration (AMD).

Phase:

Phase 1

Details

Lead Sponsor:

Ocular Therapeutix, Inc.

Treatments:

Aflibercept
Bevacizumab
Ranibizumab